key: cord-0776481-oosnpniq authors: Nguyen, Cristina; Shwe, Samantha; Yale, Katerina; Ghigi, Alessandro; Zheng, Kai; Mesinkovska, Natasha Atanaskova; Bhutani, Tina title: The role of gender, race, and ethnicity in psoriasis patients with COVID-19 infection: A cross-sectional study date: 2022-03-21 journal: Int J Womens Dermatol DOI: 10.1097/jw9.0000000000000012 sha: 8bfeaedcdb368df776ce11d57a0b7e9e90f99cce doc_id: 776481 cord_uid: oosnpniq nan When analyzing race and ethnicity data, patients without psoriasis had higher COVID-19 infection (8.4%) and hospitalization rates (23.7%) in Hispanic patients compared with non-Hispanic patients (2.0%, 19.9%, P < .00001) ( Table 2) . Similarly, within the psoriasis subset, Hispanic patients had higher infection (7.2%) and hospitalization rates (26.7%) compared with non-Hispanic patients (1.9%, P < .00001; 19.6%, P = .1120, respectively). Psoriasis patients did not have increased risk for COVID-19 infection, hospitalization, or mortality, regardless of treatment modality. This may be due to interleukin-17 or tumor necrosis factor-alpha blockade that ameliorates the inflammatory cytokine storm implicated in the sequelae of COVID-19 infection, 3 and better precautions taken by patients on biologics or immunosuppressive treatments. 5 Racial disparities depicted from our study results suggest that health inequalities may be further exacerbated by the pandemic. Limitations include the small sample size of COVID-19 positive patients with psoriasis, use of tertiary center data, de-identified data with lack of clinical details, or follow-up. Future studies with identifiable datasets and analysis of gender influences within the Hispanic population will help better assess this relationship. Understanding the mechanisms underlying COVID-19 susceptibility is fundamental to developing better guidelines for populations at risk. What is known about this subject in regard to women and their families? • Psoriasis affects men and women equally, with increased incidence in adults compared with children. • Psoriasis severity may vary due to demographics, geography, and presence of comorbidities. • Comorbid conditions associated with psoriasis, such as cardiovascular and metabolic disease, may increase risk for poor outcomes associated with COVID-19 infection. • Female patients with psoriasis did not have increased risk of COVID-19 infection, hospitalization, or mortality compared with female patients without psoriasis. • Biologic medications did not increase risk of COVID-19 infection, hospitalization, or mortality in patients with psoriasis. • Hispanic patients had significantly higher rates of COVID-19 infection and hospitalization compared with non-Hispanic patients, suggesting racial and ethnic disparities may be exacerbated by the pandemic. None. The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR001414. N/A. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. n (%) n (%) P a n (%) P a n (%) P a n (%) PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study Does biological therapy protect against severe COVID-19 COVID-19 and psoriasis: biologic treatment and challenges [Online ahead of print California Health creates centralized data set to accelerate COVID-19 research Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment